• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis.生物制剂的疗效能持续多久？银屑病生物制剂复发时间及反弹可能性的最新情况
Psoriasis Forum. 2010 Summer;16(2):36-42.
2
An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.英夫利昔单抗、依那西普、依法利珠单抗和阿法赛特作为银屑病生物治疗药物的概述。
Clin Ther. 2003 Oct;25(10):2487-505. doi: 10.1016/s0149-2918(03)80313-2.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
4
Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.补骨脂素加紫外线 A 疗法与生物制剂治疗中重度慢性斑块状银屑病的疗效比较：患者登记处的回顾性数据分析。
Br J Dermatol. 2011 Sep;165(3):640-5. doi: 10.1111/j.1365-2133.2011.10396.x. Epub 2011 Jul 11.
5
Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.在德国，与其他生物制剂相比，司库奇尤单抗作为中度至重度银屑病的一线生物治疗的成本效益。
J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-2199. doi: 10.1111/jdv.15047. Epub 2018 Jun 27.
6
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.依那西普和依法利珠单抗治疗银屑病：一项系统评价。
Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. doi: 10.3310/hta10460.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块型银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5.
8
Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.生物制剂治疗中重度银屑病的疗效：一项随机对照试验的网络荟萃分析。
Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.
9
Cost effectiveness of biologic therapies for plaque psoriasis.生物制剂治疗斑块状银屑病的成本效益。
Am J Clin Dermatol. 2013 Aug;14(4):315-26. doi: 10.1007/s40257-013-0030-z.
10
Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.阿法赛特、依法利珠单抗、依那西普和英夫利昔单抗治疗中度至重度斑块状银屑病的安全性和有效性：一项随机对照试验的荟萃分析
Br J Dermatol. 2008 Aug;159(2):274-85. doi: 10.1111/j.1365-2133.2008.08673.x. Epub 2008 Jun 10.

引用本文的文献

1
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study.预测对治疗有反应的银屑病患者在停用不同生物制剂后的复发时间：一项为期 12 年的多中心队列研究。
Am J Clin Dermatol. 2024 Nov;25(6):997-1008. doi: 10.1007/s40257-024-00887-8. Epub 2024 Sep 16.
2
Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors.炎症性肠病的退出策略：超越抗肿瘤坏死因子
World J Clin Cases. 2023 Apr 26;11(12):2657-2669. doi: 10.12998/wjcc.v11.i12.2657.
3
Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.靶向治疗红皮病型银屑病：原理与最新进展。
Drugs. 2020 Apr;80(6):525-534. doi: 10.1007/s40265-020-01283-2.
4
Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience.生物制剂或托法替布治疗中度至重度银屑病患者的缓解持续时间和长期结局：一项15年单中心经验的对照临床试验。
Dermatol Ther (Heidelb). 2019 Sep;9(3):553-569. doi: 10.1007/s13555-019-0310-5. Epub 2019 Jul 3.
5
A non-inferiority randomized controlled clinical trial comparing Unani formulation & psoralen plus ultraviolet A sol in chronic plaque psoriasis.一项比较顺势疗法制剂和补骨脂素加紫外线 A 溶液治疗慢性斑块状银屑病的非劣效性随机对照临床试验。
Indian J Med Res. 2018 Jan;147(1):66-72. doi: 10.4103/ijmr.IJMR_249_16.
6
The metabolomics of psoriatic disease.银屑病的代谢组学
Psoriasis (Auckl). 2017;7:1-15. doi: 10.2147/PTT.S118348. Epub 2017 Jan 31.

本文引用的文献

1
Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.自身免疫性疾病中抗 TNF-α 制剂的免疫原性。
Clin Rev Allergy Immunol. 2010 Apr;38(2-3):82-9. doi: 10.1007/s12016-009-8140-3.
2
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).优特克单抗（一种人白细胞介素-12/23单克隆抗体）治疗银屑病患者的疗效和安全性：一项随机、双盲、安慰剂对照试验（PHOENIX 1）的76周结果
Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4.
3
Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.依法利珠单抗治疗台湾中重度斑块状银屑病患者的临床疗效与安全性经验：一项开放标签、单臂试验研究的结果
J Eur Acad Dermatol Venereol. 2008 Mar;22(3):345-52. doi: 10.1111/j.1468-3083.2007.02430.x. Epub 2007 Nov 14.
4
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.阿达木单抗治疗中重度银屑病：一项随机对照III期试验。
J Am Acad Dermatol. 2008 Jan;58(1):106-15. doi: 10.1016/j.jaad.2007.09.010. Epub 2007 Oct 23.
5
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.一项关于连续与间断使用依那西普治疗银屑病的随机、开放标签试验。
J Am Acad Dermatol. 2007 Apr;56(4):598-603. doi: 10.1016/j.jaad.2006.09.002. Epub 2006 Nov 17.
6
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.英夫利昔单抗持续与间歇维持治疗方案治疗中重度斑块状银屑病1年的随机对照研究
J Am Acad Dermatol. 2007 Jan;56(1):31.e1-15. doi: 10.1016/j.jaad.2006.07.017. Epub 2006 Sep 6.
7
Relapse, rebound, and psoriasis adverse events: an advisory group report.复发、反跳及银屑病不良事件：一份咨询小组报告。
J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S171-81. doi: 10.1016/j.jaad.2005.10.029.
8
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.停用然后重新开始使用依那西普治疗的银屑病患者的临床反应。
J Dermatolog Treat. 2006;17(1):9-17. doi: 10.1080/09546630500472838.
9
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.英夫利昔单抗用于中重度银屑病的诱导和维持治疗：一项III期多中心双盲试验。
Lancet. 2005;366(9494):1367-74. doi: 10.1016/S0140-6736(05)67566-6.
10
Update on the mechanisms and efficacy of biological therapies for psoriasis.
J Dermatol Sci. 2005 May;38(2):75-87. doi: 10.1016/j.jdermsci.2005.01.011. Epub 2005 Mar 5.

生物制剂的疗效能持续多久？银屑病生物制剂复发时间及反弹可能性的最新情况

How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis.

作者信息

Kamaria Monique, Liao Wilson, Koo J Y

机构信息

University of Illinois, Chicago, Illinois.

Department of Dermatology, University of California, San Francisco, California.

出版信息

Psoriasis Forum. 2010 Summer;16(2):36-42.

PMID:25346591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4205949/
Abstract

The biologic agents vary considerably in terms of their long-term duration of effect. Using the definitions provided by the National Psoriasis Foundation Medical Board, the objective of this review was to compare all biologic agents with respect to time to relapse and potential for rebound. Overall, alefacept had the longest off-treatment benefit (29.9 weeks in Psoriasis Area and Severity Index [PASI] 75 responders), followed by ustekinumab (22 weeks), infliximab (19.5 weeks), adalimumab (18 weeks), etanercept (12.1 weeks in PASI 50 responders), and, lastly, efalizumab (9.6 weeks). Rebound was reported commonly for efalizumab (14%) and, extremely rarely, for etanercept (0.002%).

摘要

生物制剂在其长期疗效方面差异很大。根据美国国家银屑病基金会医学委员会提供的定义，本综述的目的是比较所有生物制剂在复发时间和反弹可能性方面的情况。总体而言，阿法赛特停药后受益时间最长（银屑病面积和严重程度指数[PASI]改善75%的患者为29.9周），其次是乌司奴单抗（22周）、英夫利昔单抗（19.5周）、阿达木单抗（18周）、依那西普（PASI改善50%的患者为12.1周），最后是依法利珠单抗（9.6周）。依法利珠单抗（14%）常见有反弹报告，依那西普则极为罕见（0.002%）有反弹报告。